###### Strengths and limitations of this study

-   This cohort has up-to-date coronary angiographic information on all included subjects. While the majority of participants has confirmed obstructive coronary artery disease (CAD), there is a sufficiently large internal comparison group which is evidentially free from any detectable CAD.

-   In addition, we are able to differentiate a group with non-obstructive CAD, constituting an interesting intermediate group. This differentiation is particularly important in terms of working with distinct phenotypes.

-   In addition to comprehensive clinical information, we assessed functional status, lifestyle factors and genetics.

-   A high quality biobank was established.

-   A potential weakness is that patients were only recruited from one tertiary care hospital. Therefore, the results may not be readily generalised to other patients with CAD.

Introduction {#s1}
============

Ischaemic heart disease accounts for \>20% of all deaths in Europe.[@R1] Although age-adjusted mortality rates from coronary artery disease (CAD) have declined substantially in the past decades throughout Europe and the USA, the CAD burden remains high.[@R1]

Traditional modifiable risk factors for CAD perform well in predicting the risk of developing CAD and targeting them decreases cardiovascular risk in a dose-dependent manner.[@R4]

Still, about half of patients with prevalent CAD remain at very high residual risk of recurrent events despite optimally controlled risk factors.[@R5] Identification of additional modifiable risk factors to reduce---residual---cardiovascular risk is essential. Novel biomarkers and assessment of the individual genetic profile bear the potential of improving risk assessment and management in both primary and secondary prevention.

In this regard, lipoprotein(a) (Lp(a)) has emerged as a novel independent risk factor for CAD.[@R6] Lp(a), whose serum level is largely genetically determined, is still a subject of controversy.[@R6] For example, the underlying physiological function of this lipoprotein is still unknown. There is reasonable evidence that Lp(a) is causally associated with CAD,[@R8] positively associated with coronary lesion severity and an independent risk factor for major adverse cardiovascular events, that is, the progression of CAD in patients with stable CAD who received optimal medical therapy.[@R7]

Screening for elevated Lp(a) presently is recommended in those at intermediate or high CV risk, in particular as an additional risk indicator.[@R7] To note, Lp(a) has also been suggested as a potential therapeutic target,[@R12] and an antisense oligonucleotide specific to apolipoprotein (a) has been recently shown to lead to dose-dependent reductions in average Lp(a) levels of \>80%.[@R13]

Obviously, patients with prevalent CAD are a very heterogeneous group. Therefore, discrimination is likely to be advantageous over a one fits all disease management strategy. Further improvements in the management of CAD will presuppose careful characterisation of different phenotypes and subsequent joint application of genetics, epigenetics and metabolomics. For this purpose, we established the LipidCardio Study in 2016. We sought to implement detailed phenotyping and follow-up of patients with different severity of CAD and also without obstructive CAD to examine factors associated with the pathophysiological process and progression of cardiovascular disease (CVD). There will be a strong focus on lipoproteins and genetics. In particular, we seek to gain further insight into the role of Lp(a) in cardiovascular pathogenesis and to investigate the implications of a screening for Lp(a) in a high risk cohort of patients undergoing coronary angiography. Combining phenotype factors with genetic factors, we desire to elaborate the particular cardiovascular risk profile of patients with high Lp(a).

As another integral part of this study, we have collected ample blood specimens to hold high-quality, well-characterised biomaterials along with their clinical, genetic and demographic information for future biomedical research projects in store in a high-quality biobank.

Cohort description {#s1-1}
------------------

Patients aged 18 years and older undergoing cardiac catheterisation at a single large academic centre (Department of Cardiology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin), except those with troponin-positive acute coronary syndromes (ACS), were eligible for inclusion. Participation rate was particularly high (\>95%). Between October 2016 and March 2018, 1005 consecutive patients were enrolled. All participants gave written informed consent at the time of enrolment. Patients unable to provide informed consent were excluded from the study.

The main study variables are shown in [online supplementary table 1](#SP1){ref-type="supplementary-material"}. A comprehensive data collection was performed, with a strong focus on cardiovascular health. Blood specimens were collected at the time of cardiac catheterisation (after administration of heparin), either as arterial blood sample directly from the radial or femoral artery sheath or as a venous blood sample from peripheral intravenous access. At enrolment, patients were interviewed to collect information on demographic characteristics, over-the-counter medication usage, health behaviours (alcohol/drug use, smoking and physical activity), a detailed standardised family history was obtained, and a screening test for cognitive impairment, the mini-mental state examination (MMSE), was performed. Information on regular prescription medications were obtained from the patients' medication plan. In addition, electronic medical records were reviewed by study personnel to obtain previous diagnoses of chronic conditions, as well as to document previous angiographic findings and coronary revascularisation history.
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### Specimens {#s1-1-1}

Portions of the blood specimens were used to determine a basic panel of laboratory tests essential to this study. Lp(a) was determined using a turbidimetric assay (Roche Diagnostics GmbH, Mannheim). Lp(a) is given in nmol/L, correctly reflecting the number of Lp(a) particles.[@R14] A range of other parameters were taken over from the hospital information system, provided that they were ordered as part of the clinical routine. Importantly, all tests were done in one central, accredited laboratory.

EDTA blood samples were frozen immediately following collection at −80°C until DNA was isolated using the sbeadex livestock kit (LGC Genomics GmbH, Germany). Selected single nucleotide polymorphisms (SNPs) were genotyped using KASP chemistry (LGC, Hoddesdon, UK). We have also determined the two biomarkers, relative leukocyte telomere length and DNA methylation age (epigenetic clock), which was described elsewhere in detail.[@R15]

Additional blood samples were drawn and stored in the Central Biomaterial Bank Charité (ZeBanC),[@R16] providing the opportunity for additional measurements at a later date.

### Coronary angiography {#s1-1-2}

Cardiac catheterisation and coronary angiography were performed according to the standard protocols of the Interventional Cardiology Unit and by discretion of the interventional cardiologist. The interventional cardiologist routinely documented diagnostic findings. Comprehensive angiographic results at the time of enrolment were recorded in the study database.

### Echocardiography, blood pressure measurement and pulse wave analysis {#s1-1-3}

Echocardiography was performed as a part of the clinical routine and selected parameters were taken over into the study database.

Blood pressure was measured once on each arm, in a sitting position and at rest with a Boso Medicus Uno device with an adequate cuff size.

Central blood pressure, pulse wave reflection and pulse wave velocity were measured with the Mobil-O-Graph PWA device, according to the operating instructions of the manufacturer.

### Other measurements {#s1-1-4}

Waist circumference was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Hip circumference was measured around the widest portion of the buttocks, with the tape parallel to the floor. For both measurements, the subjects were standing and wore little clothing.[@R17]

Hand grip strength was measured with a Smedley Dynamometer (Saehan, Type SH5002).

### Questionnaires {#s1-1-5}

The Seattle Angina Questionnaire and the Rapid Assessment of Physical Activity questionnaire were administered. Folstein's MMSE for screening of cognitive impairment was administered in face-to-face interviews by trained study personnel.

Planned follow-up measures {#s1-2}
--------------------------

Mortality information will be obtained from the obligatory registry office in 2 year intervals. Follow-up phone interviews will be conducted by trained study personnel, and the calls are planned to be made at 3 and 6 years after initial enrolment. Adverse CVD events, including non-fatal myocardial infarction, ACS, heart failure, hospitalisations, cardiac procedures (eg, revascularisation), strokes and peripheral arterial disease events will be recorded. Additional information will be collected on follow-up coronary angiogram data, development of comorbidities (hypertension, diabetes, cardiac arrhythmia, valvular heart disease, obstructive sleep apnoea and cancer) and changes in medications.

Patient and public involvement {#s1-3}
------------------------------

Patients and public were not involved in the design or conduct of this study. Lp(a) plasma levels were disclosed to the participants.

Findings to date {#s1-4}
----------------

### The cohort {#s1-4-1}

Baseline characteristics of the 1005 patients are shown in [tables 1 and 2](#T1 T2){ref-type="table"}. The mean age at enrolment was 70.9±11.1 years. Approximately 70% of the participants were male and 97.6% were of white Caucasian ancestry. Coronary angiography provided evidence of obstructive CAD (defined as \>50% luminal narrowing in a major epicardial vessel) in 69.9% of participants at enrolment, 11.2% had non-obstructive CAD and 18.8% had normal coronary angiograms without evidence of atherosclerosis (no apparent CAD). In 509 patients (50.6%) obstructive CAD had been previously known, and angiography was performed for evaluation of disease progression or planned intervention of residual stenosis.

###### 

Baseline characteristics of the LipidCardio Study, total and according to presence or absence of elevated lipoprotein(a) (≥107 nmol/L).

                                            Total        Lp(a)\<107 nmol/L   Lp(a)≥107 nmol/L
  ----------------------------------------- ------------ ------------------- ------------------
  Sex, male                                 701 (69.8)   554 (71.5)          126 (65.3)
  Age, years                                70.9±11.1    70.7±11.4           71.7±9.9
  Caucasian ancestry                        981 (97.6)   756 (97.6)          188 (97.4)
  Previous diagnosis of CAD                 509 (50.7)   374 (48.3)          115 (59.6)
  Previous bypass surgery                   77 (7.7)     51 (6.6)            24 (12.4)
  Previous myocardial infarction            310 (30.9)   227 (29.3)          61 (36.8)
  Total obstructive CAD                     701 (69.9)   526 (67.9)          151 (78.2)
   One vessel                               156 (15.5)   122 (15.7)          27 (14.0)
   Two vessel                               234 (23.3)   174 (22.5)          53 (27.5)
   Three vessel                             311 (31.0)   230 (29.7)          71 (36.8)
  Non-obstructive CAD                       113 (11.2)   94 (12.1)           14 (7.3)
  No apparent CAD                           170 (16.9)   155(20)             28 (14.5)
  Aortic valve stenosis                     100 (12.2)   71 (11.2)           26 (16.4)
  Previous stroke                           98 (9.8)     71 (9.2)            24 (12.4)
  Atrial fibrillation                       273 (27.2)   214 (27.6)          49 (25.4)
  Diabetes mellitus type 2                  270 (26.9)   220 (28.4)          43 (22.3)
  Hypertension                              813 (81.0)   627 (80.9)          156 (80.8)
  Dyslipidaemia                             598 (59.6)   455 (58.7)          121 (62.7)
  Cancer                                    181 (18.0)   136 (17.6)          42 (21.8)
  PAD                                       91 (9.1)     64 (8.3)            23 (11.9)
  CKD                                       164 (16.3)   121 (15.6)          35 (18.1)
  COPD                                      109 (10.8)   87 (11.2)           17 (8.8)
  LDL-C (mg/dL)                             99.1±40.6    97.1±39.8           106.4±41.9
  ApoA1 (g/L)                               1.28±0.28    1.27±0.28           1.32±0.27
  ApoB (g/L)                                0.85±0.27    0.83±0.27           0.93±0.28
  WC (cm)                                   101.7±14.1   102.1±14.4          100.6±13.6
  Systolic blood pressure (mm Hg)           134.0±21.3   134.0±21.5          134.3±21.1
  Statin therapy                            608 (60.5)   459 (59.2)          129 (66.8)
  eGFR CKD-EPI formula (mL/min/1.73 m^2^)   70.0±19.7    70.4±19.7           69.2±19.6
  eGFR \<60 mL/min/1.73 m^2^                290 (29.8)   218 (29.3)          59 (30.9)

Values are mean±SD and n(%) unless stated otherwise. Of n=1005 observations values were missing in Lp(a) (n=37), LDL-C (n=41), ApoA1 (n=50), ApoB (n=49), WC (n=153), systolic blood pressure (n=148) and eGFR (n=33).

AF, atrial fibrillation; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; CAD, coronary artery disease; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease-epidemiology collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); PAD, peripheral arterial disease; WC, waist circumference.

###### 

Baseline characteristics by CAD status at baseline.

                                     No apparent CAD    Obstructive CAD    Non-obstructive CAD   
  ---------------------------------- ------------------ ------------------ --------------------- -------------------
                                                        **Prior**          **Newly diagnosed**   
                                     187 (18.6%)        509 (50.8%)        200 (19.9%)           107 (10.7%)
  Age (years)                        66.2±12.9          72.0±10.7          71.9±9.8              72.3±9.2
  Sex (female)                       107 (57.2)         95 (18.7)          58 (29.0)             42 (39.3)
  Diabetes mellitus 2                38 (20.3)          157 (30.8)         52 (26.0)             23 (21.5)
  Dyslipidaemia                      80 (42.8)          354 (69.8)         107 (53.5)            56 (52.3)
  Smoking (current)                  33 (20.8)          82 (17.9)          40 (22.2)             15(15)
  Smoking (former)                   61 (48.4)          247 (65.7)         81 (57.9)             44 (51.8)
  LDL-C (mg/dL)                      115.00±37.60       85.20±35.13        117.75±44.40          104.38±37.53
  HDL-C (mg/dL)                      56.76±17.76        47.84±15.34        50.91±15.19           55.82±18.30
  Triglycerides (mg/dL)              112 (88--156)      120 (89--174)      124 (89--185)         119 (89--158)
  Lp(a) (nmol/L)                     17.4 (7.2--60.3)   20.5 (5.0--99.8)   22.3 (7.2--71.4)      15.30 (5.0--44.4)
  Lp(a)\>106.9 nmol/L                28 (15.5)          115 (23.5)         37 (19.0)             13 (12.6)
  Glucose (mg/dL)                    115.0±37.3         123.1±47.1         125.7±47.7            121.9±44.6
  HbA1c (%)                          5.70±0.70          6.00±0.84          5.99±0.89             5.78±0.81
  ApoB (g/L)                         0.93±0.24          0.77±0.25          0.95±0.30             0.89±0.27
  Chronic kidney disease             36 (20.3)          175 (34.9)         55 (29.1)             23 (22.3)
  eGFR~CKD-EPI~ (mL/min/1.73 m^2^)   75.4±20.4          68.3±19.4          70.1±21.0             69.5±15.1
  ApoA1 (g/L)                        1.39±0.31          1.23±0.26          1.30±0.25             1.33±0.27
  Body mass index (kg/m^2^)          27.89±5.05         27.83±4.70         27.58±5.03            27.75±5.40
  C reactive protein (mg/L)          2.15 (1.1--9.1)    2.0 (0.9--6.9)     2.8 (1.1--7.6)        2.30 (0.8--7.0)
  Systolic blood pressure (mm Hg)    131.96±20.40       133.3±21.5         138.3±20.8            132.48±20.37
  Diastolic blood pressure (mm Hg)   80.6±13.0          76.5±13.8          80.5±14.1             76.1±10.9

Values are mean±SD and n(%), or median (25th--75th percentile) unless stated otherwise. Of 1003 observations, values were missing in DBP (n=148), SBP (n=148), CRP (n=300), BMI (n=111), ApoA1 (n=48), smoking current (n=105), smoking former (n=276), LDL-C (n=41), HDL-C (n=46), triglycerides (n=289), Lp(a) (n=35), glucose (n=250), HbA1c (n=22), ApoB (n=47), chronic kidney disease (n=33) and eGFR~CKD-EPI~ (n=33).

ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; CAD, coronary artery disease; CKD-EPI, chronic kidney disease-epidemiology collaboration; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Those with evidence of obstructive CAD were significantly more likely to have a positive family history of CVD (OR 1.48, 95% CI 1.06 to 2.06, p=0.019), compared with participants with no apparent CAD. Likewise, participants with obstructive CAD were significantly more likely to be physically inactive (OR 1.50, 95% CI 1.09 to 2.16, p=0.014).

Lipoprotein(a): clinical and genetic associations {#s1-5}
-------------------------------------------------

The median serum concentration of Lp(a) at baseline was 19.3 nmol/L (IQR\<7.0--77.1 nmol/L). Lp(a) levels were positively associated with age among women, whereas in men Lp(a) levels were consistent across the age spectrum. Referring to this, whereas overall there was no evidence of a significant sex difference in Lp(a) levels, in patients aged over 60 years the median Lp(a) concentration was significantly higher in women (26.4; IQR 8.2--109.6) than in men (18.2; IQR \<7.0--71.4, p=0.038).

Accounting for the right-skewed distribution of Lp(a) in the general population and also in cardiovascular high-risk populations, it has become current practice to examine the distribution of Lp(a) by quintiles, particularly individuals in the fifth quintile being at increased risk of CV disease. Also, the commonly referenced threshold of 100--125 nmol/L (equals 50 mg/dL), usually corresponds approximately to the cut-off point defining the fifth quintile.[@R6] Of total 968 patients with available Lp(a) measurements, 193 patients (19.9%) had Lp(a) values above 106.9 nmol/L (fifth quintile).

Participants in the highest quintile of Lp(a) (≥107 nmol/L) had significantly increased odds of obstructive CAD compared with participants in the lowest quintile (OR 1.58, 1.02 to 2.45, p=0.039) or in quintiles 1--4 (OR 1.7, 95% CI 1.17 to 2.48, p=0.005), respectively. Moreover, there was reasonable evidence that with increasing severity of CAD (non obstructive CAD, 1-vessel, 2-vessel and 3-vessel obstructive CAD) the odds of having a significantly elevated Lp(a) increased (test for trend p=0.015).

### Genetic associations {#s1-5-1}

In order to assess if our cohort data are suitable for genetic association analyses, we genotyped and examined *LPA*-SNPs rs10455872, rs3798220 and rs186696265, which have been previously reported to be strongly associated with Lp(a) serum levels.[@R19] Overall, 179 patients (18.8%) were carriers of at least one minor allele. All three SNPs were significantly associated with Lp(a) levels in the LipidCardio cohort ([table 3](#T3){ref-type="table"}). The strongest evidence of an association with Lp(a) serum levels was found for rs10455872 (β=0.794; p=5.1×10^−52^, [table 3](#T3){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). Our data were compatible with an overall positive association (OR 1.35; 95 % CI 0.93 to 1.99, p=0.118) between carrying a minor *LPA* variant and CAD; even though the evidence was week. However, when stratified by sex there was reasonable evidence to suggest an association between the *LPA*-SNPs tested and obstructive CAD in women (OR 1.85, 95% CI 1.02 to 3.35, p=0.04), while in men there was no evidence for such an association. The association in women was stable even after adjusting for age, type 2 diabetes, LDL-C and statin therapy.

![Association between single nucleotide polymorphism rs10455872 and lipoprotein(a) (Lp(a)) in the LipidCardio sample. rs10455872 genotype was significantly associated with median Lp(a) values (interquartile ranges are indicated, n=933). The p value was determined using the Kruskal-Wallis test.](bmjopen-2019-030097f01){#F1}

###### 

Associations of *LPA*-single nucleotide polymorphisms (*LPA*-SNPs) and lipoprotein(a) (Lp(a)) serum levels: linear regression analysis on Lp(a) serum levels (log10-transformed), adjusted for age and sex

  ------------------------------------------------------------------------------------------------------------
  SNP           Location (GRCh37.p13)   A1/A2\           MAF      N^1^   β       SE      P value        N^2^
                                        (call rate, %)                                                  
  ------------- ----------------------- ---------------- -------- ------ ------- ------- -------------- ------
  rs10455872    6:160589086             A/G (99.6)       0.0736   950    0.794   0.049   5.10×10^−52^   933

  rs3798220     6:160540105             C/T(99.9)        0.0236   953    0.865   0.092   3.93×10^−20^   936

  rs186696265   6:160690668             C/T (99.8)       0.0170   952    0.993   0.106   7.60×10^−20^   935

  rs429358      19:44908684             C/T(95.4)        0.1307   910    0.035   0.043   0.407          893

  rs7412        19:44908822             C/T(99.9)        0.0692   953    0.150   0.057   0.008          936
  ------------------------------------------------------------------------------------------------------------

A1/A2, allele 1/allele 2; Lp(a) association, genotype and Lp(a) level available; MAF, allele frequency of the minor allele in LipidCardio; N^1^, number of genotyped samples; N^2^, number analysed with respect to.

Furthermore, we genotyped the two SNPs rs429358 and rs7412 constituting the three isoforms of apolipoprotein E (APOE) apoE2, apoE3 and apoE4. Rs7412 was recently confirmed in a large genome-wide association meta-analysis to be associated with Lp(a) serum levels with genome wide significance.[@R19] Indeed, we found rs7412 to be significantly associated with Lp(a) concentration (β=0.15; p=0.008), that is, we could replicate the previous finding. Similar to the earlier study, there was no evidence that rs429358 was also associated with Lp(a) serum levels in the LipidCardio cohort (data not shown), while there was reasonable evidence of an association between the inferred APOE isoforms ([online supplementary table 2](#SP1){ref-type="supplementary-material"}) and Lp(a) serum levels (β=0.015; p=0.006, n=893) (see [online supplementary table 2](#SP1){ref-type="supplementary-material"}).
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